Health
DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
TOKYO & BASKING RIDGE, N.J., October 06, 2025--Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/210d8a2f477385feed794a8cf249a69d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J10NBS8oyudOyyEwG5QSyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/210d8a2f477385feed794a8cf249a69d","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population","length":160,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"DATROWAY also demonstrated a highly statistically significant and clinically meaningful improvement in the dual primary endpoint of progression-free survival","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Plans for global regulatory submissions are underway","length":52,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":369,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 06, 2025--(BUSINESS WIRE)--Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option.","length":559,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":231,"tagName":"p"},{"type":"text","content":"Approximately 70% of patients with metastatic TNBC are not candidates for immunotherapy, including all patients whose tumors do not express PD-L1 as well as patients with PD-L1 expressing tumors who cannot receive immunotherapy due to other factors.1 Chemotherapy rema...